p27kip1: A Target for Tumor Therapies
Author Information
Author(s): Nickeleit Irina, Zender Steffen, Kossatz Uta, Malek Nisar P
Primary Institution: Hannover Medical School, Hannover, Germany
Hypothesis
Could p27kip1 be a valuable target for pharmaceutical intervention in cancer therapies?
Conclusion
Therapies aimed at stabilizing p27 could be clinically beneficial, but there are potential risks associated with its stabilization.
Supporting Evidence
- Reduced p27 levels in cancer tissues correlate with poor patient prognosis.
- Loss of p27 in mouse models leads to increased cancer susceptibility.
- Re-expression of p27 in tumor cells can induce apoptosis.
- Stabilizing p27 may prevent tumor cell de-differentiation.
Takeaway
p27kip1 is a protein that helps stop cancer cells from growing, and scientists are looking for ways to keep it from breaking down too quickly in tumors.
Methodology
This review summarizes experimental results regarding the role of p27kip1 in cancer and its potential as a therapeutic target.
Potential Biases
The review highlights that p27 is rarely mutated in cancers, suggesting it may have tumor-promoting functions in early tumor development.
Limitations
The review discusses potential risks of p27 stabilization therapies, including the possibility of promoting tumor growth.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website